Loading…

PON1 and PON3 in Alzheimer's Disease: Similar Functions but Different Roles

Paraoxonase 1 (PON1) and Paraoxonase 3 (PON3) are enzymes located on the surface of high-density lipoprotein (HDL) and share similar antioxidant properties, possibly modulated by other proteins such as Myeloperoxidase (MPO), which drives the shift from functional to dysfunctional HDL. PON1 has been...

Full description

Saved in:
Bibliographic Details
Published in:Antioxidants 2024-10, Vol.13 (10), p.1216
Main Authors: Trentini, Alessandro, Rosta, Valentina, Riccetti, Raffaella, Mola, Gianmarco, Galletti, Riccardo, Pinotti, Marco, Senia, Vincenza, Zuliani, Giovanni, Cervellati, Carlo
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c437t-8613267c091a85fe6a332573d566331b18afa37feafb71a95ab774a8cb3d68553
container_end_page
container_issue 10
container_start_page 1216
container_title Antioxidants
container_volume 13
creator Trentini, Alessandro
Rosta, Valentina
Riccetti, Raffaella
Mola, Gianmarco
Galletti, Riccardo
Pinotti, Marco
Senia, Vincenza
Zuliani, Giovanni
Cervellati, Carlo
description Paraoxonase 1 (PON1) and Paraoxonase 3 (PON3) are enzymes located on the surface of high-density lipoprotein (HDL) and share similar antioxidant properties, possibly modulated by other proteins such as Myeloperoxidase (MPO), which drives the shift from functional to dysfunctional HDL. PON1 has been extensively studied in relation to Alzheimer's Disease (AD), but the role of PON3 remains unknown. To fill this knowledge gap, the study analyzed PON3 protein levels and PON1-arylesterase activity in 99 AD patients, 100 patients with mild cognitive impairment (MCI), and 79 cognitively normal controls. The results showed that serum PON3 levels remained unchanged across all groups. In contrast, serum arylesterase activity was significantly reduced in both AD and MCI patients compared to controls ( < 0.001 for both comparisons). Surprisingly, there was no correlation between arylesterase activity and MPO protein concentration or activity. However, PON3 was found to have a significant positive correlation with both MPO concentration (r = 0.507, < 0.0001) and MPO activity (r = 0.264, < 0.01). In conclusion, we demonstrated for the first time that PON1 and PON3 have distinct relationships with AD, with only PON1 showing a decrease in activity in this disease, while PON3 levels remained unchanged. Another noteworthy finding was the selective correlation between PON3 and MPO, which may suggest a preferential physical association of PON3 with dysfunctional HDL.
doi_str_mv 10.3390/antiox13101216
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5807e218c6714bcbb5ac07aa9ffd9c73</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A814364121</galeid><doaj_id>oai_doaj_org_article_5807e218c6714bcbb5ac07aa9ffd9c73</doaj_id><sourcerecordid>A814364121</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-8613267c091a85fe6a332573d566331b18afa37feafb71a95ab774a8cb3d68553</originalsourceid><addsrcrecordid>eNptUk1v1DAQtRCIVtteOaJIHOCyrZ2JP8IFrQqFiooiPs7WxLG3XiV2sRME_Hq8tJQuqn3waObNm3njIeQJo0cALT3GMPn4gwGjrGbiAdmvqRRLaGv28I69Rw5z3tByWgaKto_JHrQNF41o98n7jxcfWIWhr4oBlQ_Vavh1af1o0_NcvfbZYrYvq89-9AOm6nQOptQMuermqYSds8mGqfoUB5sPyCOHQ7aHN--CfD198-Xk3fL84u3Zyep8aRqQ01IJBrWQprSDijsrEKDmEnouBADrmEKHIJ1F10mGLcdOygaV6aAXinNYkLNr3j7iRl8lP2L6qSN6_ccR01pjmrwZrOaKSlszZYRkTWe6jqOhErF1rm-NhML16prrau5G25siJuGwQ7obCf5Sr-N3zRinvC5SFuTFDUOK32abJz36bOwwYLBxzhrK31BBoZEF-uw_6CbOKZRZbVGUs7qR4h9qjUWBDy6WwmZLqleKNSCawlhQR_egyu3t6E0M1vnivy_BpJhzsu5WJKN6u056d51KwtO7o7mF_10e-A2WxcKa</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3120512476</pqid></control><display><type>article</type><title>PON1 and PON3 in Alzheimer's Disease: Similar Functions but Different Roles</title><source>ProQuest - Publicly Available Content Database</source><source>PubMed Central</source><creator>Trentini, Alessandro ; Rosta, Valentina ; Riccetti, Raffaella ; Mola, Gianmarco ; Galletti, Riccardo ; Pinotti, Marco ; Senia, Vincenza ; Zuliani, Giovanni ; Cervellati, Carlo</creator><creatorcontrib>Trentini, Alessandro ; Rosta, Valentina ; Riccetti, Raffaella ; Mola, Gianmarco ; Galletti, Riccardo ; Pinotti, Marco ; Senia, Vincenza ; Zuliani, Giovanni ; Cervellati, Carlo</creatorcontrib><description>Paraoxonase 1 (PON1) and Paraoxonase 3 (PON3) are enzymes located on the surface of high-density lipoprotein (HDL) and share similar antioxidant properties, possibly modulated by other proteins such as Myeloperoxidase (MPO), which drives the shift from functional to dysfunctional HDL. PON1 has been extensively studied in relation to Alzheimer's Disease (AD), but the role of PON3 remains unknown. To fill this knowledge gap, the study analyzed PON3 protein levels and PON1-arylesterase activity in 99 AD patients, 100 patients with mild cognitive impairment (MCI), and 79 cognitively normal controls. The results showed that serum PON3 levels remained unchanged across all groups. In contrast, serum arylesterase activity was significantly reduced in both AD and MCI patients compared to controls ( &lt; 0.001 for both comparisons). Surprisingly, there was no correlation between arylesterase activity and MPO protein concentration or activity. However, PON3 was found to have a significant positive correlation with both MPO concentration (r = 0.507, &lt; 0.0001) and MPO activity (r = 0.264, &lt; 0.01). In conclusion, we demonstrated for the first time that PON1 and PON3 have distinct relationships with AD, with only PON1 showing a decrease in activity in this disease, while PON3 levels remained unchanged. Another noteworthy finding was the selective correlation between PON3 and MPO, which may suggest a preferential physical association of PON3 with dysfunctional HDL.</description><identifier>ISSN: 2076-3921</identifier><identifier>EISSN: 2076-3921</identifier><identifier>DOI: 10.3390/antiox13101216</identifier><identifier>PMID: 39456469</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Activities of daily living ; Alzheimer's disease ; Arylesterase ; Blood ; Brain research ; Cardiovascular disease ; Cholesterol ; Cognitive ability ; Dementia ; Development and progression ; Enzymes ; Health aspects ; High density lipoprotein ; Lipoproteins ; mild cognitive impairment ; Neurodegenerative diseases ; Paraoxonase ; Paraoxonase 1 ; Peroxidase</subject><ispartof>Antioxidants, 2024-10, Vol.13 (10), p.1216</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c437t-8613267c091a85fe6a332573d566331b18afa37feafb71a95ab774a8cb3d68553</cites><orcidid>0000-0003-3579-7921 ; 0000-0003-4777-6300</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3120512476/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3120512476?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792,74897</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39456469$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Trentini, Alessandro</creatorcontrib><creatorcontrib>Rosta, Valentina</creatorcontrib><creatorcontrib>Riccetti, Raffaella</creatorcontrib><creatorcontrib>Mola, Gianmarco</creatorcontrib><creatorcontrib>Galletti, Riccardo</creatorcontrib><creatorcontrib>Pinotti, Marco</creatorcontrib><creatorcontrib>Senia, Vincenza</creatorcontrib><creatorcontrib>Zuliani, Giovanni</creatorcontrib><creatorcontrib>Cervellati, Carlo</creatorcontrib><title>PON1 and PON3 in Alzheimer's Disease: Similar Functions but Different Roles</title><title>Antioxidants</title><addtitle>Antioxidants (Basel)</addtitle><description>Paraoxonase 1 (PON1) and Paraoxonase 3 (PON3) are enzymes located on the surface of high-density lipoprotein (HDL) and share similar antioxidant properties, possibly modulated by other proteins such as Myeloperoxidase (MPO), which drives the shift from functional to dysfunctional HDL. PON1 has been extensively studied in relation to Alzheimer's Disease (AD), but the role of PON3 remains unknown. To fill this knowledge gap, the study analyzed PON3 protein levels and PON1-arylesterase activity in 99 AD patients, 100 patients with mild cognitive impairment (MCI), and 79 cognitively normal controls. The results showed that serum PON3 levels remained unchanged across all groups. In contrast, serum arylesterase activity was significantly reduced in both AD and MCI patients compared to controls ( &lt; 0.001 for both comparisons). Surprisingly, there was no correlation between arylesterase activity and MPO protein concentration or activity. However, PON3 was found to have a significant positive correlation with both MPO concentration (r = 0.507, &lt; 0.0001) and MPO activity (r = 0.264, &lt; 0.01). In conclusion, we demonstrated for the first time that PON1 and PON3 have distinct relationships with AD, with only PON1 showing a decrease in activity in this disease, while PON3 levels remained unchanged. Another noteworthy finding was the selective correlation between PON3 and MPO, which may suggest a preferential physical association of PON3 with dysfunctional HDL.</description><subject>Activities of daily living</subject><subject>Alzheimer's disease</subject><subject>Arylesterase</subject><subject>Blood</subject><subject>Brain research</subject><subject>Cardiovascular disease</subject><subject>Cholesterol</subject><subject>Cognitive ability</subject><subject>Dementia</subject><subject>Development and progression</subject><subject>Enzymes</subject><subject>Health aspects</subject><subject>High density lipoprotein</subject><subject>Lipoproteins</subject><subject>mild cognitive impairment</subject><subject>Neurodegenerative diseases</subject><subject>Paraoxonase</subject><subject>Paraoxonase 1</subject><subject>Peroxidase</subject><issn>2076-3921</issn><issn>2076-3921</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUk1v1DAQtRCIVtteOaJIHOCyrZ2JP8IFrQqFiooiPs7WxLG3XiV2sRME_Hq8tJQuqn3waObNm3njIeQJo0cALT3GMPn4gwGjrGbiAdmvqRRLaGv28I69Rw5z3tByWgaKto_JHrQNF41o98n7jxcfWIWhr4oBlQ_Vavh1af1o0_NcvfbZYrYvq89-9AOm6nQOptQMuermqYSds8mGqfoUB5sPyCOHQ7aHN--CfD198-Xk3fL84u3Zyep8aRqQ01IJBrWQprSDijsrEKDmEnouBADrmEKHIJ1F10mGLcdOygaV6aAXinNYkLNr3j7iRl8lP2L6qSN6_ccR01pjmrwZrOaKSlszZYRkTWe6jqOhErF1rm-NhML16prrau5G25siJuGwQ7obCf5Sr-N3zRinvC5SFuTFDUOK32abJz36bOwwYLBxzhrK31BBoZEF-uw_6CbOKZRZbVGUs7qR4h9qjUWBDy6WwmZLqleKNSCawlhQR_egyu3t6E0M1vnivy_BpJhzsu5WJKN6u056d51KwtO7o7mF_10e-A2WxcKa</recordid><startdate>20241010</startdate><enddate>20241010</enddate><creator>Trentini, Alessandro</creator><creator>Rosta, Valentina</creator><creator>Riccetti, Raffaella</creator><creator>Mola, Gianmarco</creator><creator>Galletti, Riccardo</creator><creator>Pinotti, Marco</creator><creator>Senia, Vincenza</creator><creator>Zuliani, Giovanni</creator><creator>Cervellati, Carlo</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QR</scope><scope>7T5</scope><scope>7TO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3579-7921</orcidid><orcidid>https://orcid.org/0000-0003-4777-6300</orcidid></search><sort><creationdate>20241010</creationdate><title>PON1 and PON3 in Alzheimer's Disease: Similar Functions but Different Roles</title><author>Trentini, Alessandro ; Rosta, Valentina ; Riccetti, Raffaella ; Mola, Gianmarco ; Galletti, Riccardo ; Pinotti, Marco ; Senia, Vincenza ; Zuliani, Giovanni ; Cervellati, Carlo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-8613267c091a85fe6a332573d566331b18afa37feafb71a95ab774a8cb3d68553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Activities of daily living</topic><topic>Alzheimer's disease</topic><topic>Arylesterase</topic><topic>Blood</topic><topic>Brain research</topic><topic>Cardiovascular disease</topic><topic>Cholesterol</topic><topic>Cognitive ability</topic><topic>Dementia</topic><topic>Development and progression</topic><topic>Enzymes</topic><topic>Health aspects</topic><topic>High density lipoprotein</topic><topic>Lipoproteins</topic><topic>mild cognitive impairment</topic><topic>Neurodegenerative diseases</topic><topic>Paraoxonase</topic><topic>Paraoxonase 1</topic><topic>Peroxidase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Trentini, Alessandro</creatorcontrib><creatorcontrib>Rosta, Valentina</creatorcontrib><creatorcontrib>Riccetti, Raffaella</creatorcontrib><creatorcontrib>Mola, Gianmarco</creatorcontrib><creatorcontrib>Galletti, Riccardo</creatorcontrib><creatorcontrib>Pinotti, Marco</creatorcontrib><creatorcontrib>Senia, Vincenza</creatorcontrib><creatorcontrib>Zuliani, Giovanni</creatorcontrib><creatorcontrib>Cervellati, Carlo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Antioxidants</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Trentini, Alessandro</au><au>Rosta, Valentina</au><au>Riccetti, Raffaella</au><au>Mola, Gianmarco</au><au>Galletti, Riccardo</au><au>Pinotti, Marco</au><au>Senia, Vincenza</au><au>Zuliani, Giovanni</au><au>Cervellati, Carlo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PON1 and PON3 in Alzheimer's Disease: Similar Functions but Different Roles</atitle><jtitle>Antioxidants</jtitle><addtitle>Antioxidants (Basel)</addtitle><date>2024-10-10</date><risdate>2024</risdate><volume>13</volume><issue>10</issue><spage>1216</spage><pages>1216-</pages><issn>2076-3921</issn><eissn>2076-3921</eissn><abstract>Paraoxonase 1 (PON1) and Paraoxonase 3 (PON3) are enzymes located on the surface of high-density lipoprotein (HDL) and share similar antioxidant properties, possibly modulated by other proteins such as Myeloperoxidase (MPO), which drives the shift from functional to dysfunctional HDL. PON1 has been extensively studied in relation to Alzheimer's Disease (AD), but the role of PON3 remains unknown. To fill this knowledge gap, the study analyzed PON3 protein levels and PON1-arylesterase activity in 99 AD patients, 100 patients with mild cognitive impairment (MCI), and 79 cognitively normal controls. The results showed that serum PON3 levels remained unchanged across all groups. In contrast, serum arylesterase activity was significantly reduced in both AD and MCI patients compared to controls ( &lt; 0.001 for both comparisons). Surprisingly, there was no correlation between arylesterase activity and MPO protein concentration or activity. However, PON3 was found to have a significant positive correlation with both MPO concentration (r = 0.507, &lt; 0.0001) and MPO activity (r = 0.264, &lt; 0.01). In conclusion, we demonstrated for the first time that PON1 and PON3 have distinct relationships with AD, with only PON1 showing a decrease in activity in this disease, while PON3 levels remained unchanged. Another noteworthy finding was the selective correlation between PON3 and MPO, which may suggest a preferential physical association of PON3 with dysfunctional HDL.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39456469</pmid><doi>10.3390/antiox13101216</doi><orcidid>https://orcid.org/0000-0003-3579-7921</orcidid><orcidid>https://orcid.org/0000-0003-4777-6300</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2076-3921
ispartof Antioxidants, 2024-10, Vol.13 (10), p.1216
issn 2076-3921
2076-3921
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_5807e218c6714bcbb5ac07aa9ffd9c73
source ProQuest - Publicly Available Content Database; PubMed Central
subjects Activities of daily living
Alzheimer's disease
Arylesterase
Blood
Brain research
Cardiovascular disease
Cholesterol
Cognitive ability
Dementia
Development and progression
Enzymes
Health aspects
High density lipoprotein
Lipoproteins
mild cognitive impairment
Neurodegenerative diseases
Paraoxonase
Paraoxonase 1
Peroxidase
title PON1 and PON3 in Alzheimer's Disease: Similar Functions but Different Roles
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T08%3A27%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PON1%20and%20PON3%20in%20Alzheimer's%20Disease:%20Similar%20Functions%20but%20Different%20Roles&rft.jtitle=Antioxidants&rft.au=Trentini,%20Alessandro&rft.date=2024-10-10&rft.volume=13&rft.issue=10&rft.spage=1216&rft.pages=1216-&rft.issn=2076-3921&rft.eissn=2076-3921&rft_id=info:doi/10.3390/antiox13101216&rft_dat=%3Cgale_doaj_%3EA814364121%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c437t-8613267c091a85fe6a332573d566331b18afa37feafb71a95ab774a8cb3d68553%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3120512476&rft_id=info:pmid/39456469&rft_galeid=A814364121&rfr_iscdi=true